<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369602</url>
  </required_header>
  <id_info>
    <org_study_id>B2611011</org_study_id>
    <nct_id>NCT01369602</nct_id>
  </id_info>
  <brief_title>Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532</brief_title>
  <official_title>A Phase 1, Single-Dose, Open-Label Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the pharmacokinetics, safety and
      tolerability of a single oral dose of PF-04991532 in subjects with renal impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUClast)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (Clr)</measure>
    <time_frame>0 to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of drug excreted (Ae)</measure>
    <time_frame>0 to 24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy subjects (creatinine clearance &gt; 90 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESRD / severe renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe (creatinine clearance 15 to 29 mL/min) OR ESRD (creatinine clearnace &lt;15 mL/min OR requiring dialysis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate (creatinine clearance = 30 to 59 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild (creatinine clearance = 60 to 89 mL/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04991532</intervention_name>
    <description>single dose 300-mg</description>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04991532</intervention_name>
    <description>single dose 300-mg</description>
    <arm_group_label>ESRD / severe renal insufficiency</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04991532</intervention_name>
    <description>single dose 300-mg</description>
    <arm_group_label>Moderate renal impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04991532</intervention_name>
    <description>single dose 300-mg</description>
    <arm_group_label>Mild renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable renal function defined as &lt;20% difference between two measurements of serum
             creatinine obtained on two occasions separated by at least 72 hours to 14 days; the
             second determination must be obtained within the 28-day period prior to the start of
             study medication administration. CrCl value at Screening (average of two values
             obtained within two weeks apart before dosing) will be used for study enrollment.

          -  Body Mass Index (BMI) of 17.5 to 40 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Pregnant or nursing females; females of childbearing potential who are unwilling or
             unable to use an acceptable method of nonhormonal contraception as outlined in this
             protocol from at least 14 days prior to the first dose of study medication.

          -  Subjects with recent (within the last 6 months) history of myocardial infarction,
             unstable angina, coronary revascularization, stroke or transient ischemic attack
             (TIA).

          -  Subjects with severe heart failure (New York Heart Association Functional Class IV) at
             Screening.

          -  Subjects with acute renal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2611011&amp;StudyName=Study%20To%20Evaluate%20The%20Effect%20Of%20Renal%20Impairment%20On%20The%20Pharmacokinetics%20Of%20PF-04991532</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>February 21, 2012</last_update_submitted>
  <last_update_submitted_qc>February 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

